Tirzepatide inova mbiri-glucose-inotsamira insulinotropic polypeptide (GIP) uye glucagon-yakafanana peptide-1 (GLP-1) receptor agonist yakagadzirwa. Maitiro ayo maviri ane chinangwa chekuwedzera insulin secretion, kudzvanya kuburitswa kweglucagon, kunonoka kubuda mudumbu, uye kugadzirisa satiety, ichipa yakazara nzira yekurapa yerudzi rwechipiri chirwere cheshuga mellitus (T2DM) uye kufutisa.
Zvakawanikwa Zvikuru kubva kuClinical Studies
1. Glycemic Control
Kupfuura akawandaSURPASSchikamu 3 kliniki miedzo, tirzepatide yakaratidzayepamusoro glycemic controlzvichienzaniswa neapo antidiabetic agents, kusanganisira semaglutide uye insulin degludec.
-
Zvinoreva HbA1c kuderedza: kusvika−2.4%kubva pakutanga mushure memavhiki 40-52.
-
Chikamu chepamusoro chevatori vechikamu chakaitwaHbA1c <6.5%, kusangana kana kudarika zvinangwa zveADA.
-
Kuvandudzika kwakakosha mukutsanya plasma glucose uye postprandial glucose mazinga akaonekwa.
2. Kuderedza uremu
Tirzepatide inogara ichigadzirwakukiriniki kunoreva uye kunoenderana nedosi kurasikirwa uremumuvanhu vane chirwere cheshuga nevasiri vane chirwere cheshuga.
-
Mune T2DM varwere: avhareji uremu kuderedzwa kubva7–12 kg.
-
Mune vasiri-diabetic obese zvidzidzo (SURMOUNT-1 kuyedzwa):
-
10 mg uye 15 mg doses yakatungamirira kune15-22% inoreva kuora muviri, inofananidzwa kana kudarika zvikumbaridzo zvekuvhiyiwa kwebariatric.
-
-
Vazhinji vatori vechikamu vakabudirira5–10%kuderedza uremu.
3. Cardiometabolic Improvements
Tirzepatide kurapwa zvakare yakavandudza yakakura metabolic paramita:
-
Kuderedzwamu triglycerides, LDL-C, uye cholesterol yakazara.
-
InowedzeramuHDL-C.
-
Chinokoshakuderera kwe systolic uye diastolic blood pressure.
-
Kuvandudzwa kwe insulin senitivity uye β-cell basa.
4. Kuchengeteka uye Kushivirira
Iyo nhoroondo yekuchengetedza yaienderana nemamwe incretin-based therapies:
-
Zviitiko zvinowanzoitika zvakashata: zvinyoro-kusvika-zvine mwero zviratidzo zvemudumbu (kusvotwa, kurutsa, manyoka).
-
Yakaderera chiitiko che hypoglycemia, kunyanya kana ichishandiswa ne insulin kana sulfonylureas.
-
Hapana kunyanya kunetseka kwekuchengetedza kunoonekwa mumhedzisiro yemoyo.
5. Mechanistic Insights
Tirzepatide yakasarudzikadual receptor agonisminokudza zvose GIP uye GLP-1 nzira:
-
GIP activationinowedzera glucose-inotsamira insulin secretion uye inogona kuvandudza adipose tishu metabolism.
-
GLP-1 activationkunokurudzira kudzvinyirirwa kwechido uye kunonotsa kubuda mudumbu.
-
Zvavosynergistic effectinotungamira kune yakagadziridzwa kutonga kweglucose nekuwedzeredzwa uremu kuderedzwa kana ichienzaniswa nevamiriri venzira imwe chete.
Mhedziso
Tirzepatide inomiririra akubudirira mune metabolic therapy, kupakusati kwamboitika kushanda mune zvese glycemic control uye uremu kuderedzakune vanhu vane Type 2 chirwere cheshuga uye kufutisa.
Yayo mbiri incretin mashandiro inopa nzira yakabatanidzwa yekugadzirisa izvo zvinokonzeresa metabolic dysfunction - hyperglycemia, insulin kuramba, uye kuwanda kwehuremu hwemuviri.
Nekuda kwekuita kwayo kwakasimba uye inogoneka kuchengetedza chimiro, tirzepatide inogona kutsanangudza paradigm yekurapa kwechirwere cheshuga uye kufutisa manejimendi mumakore gumi ari kuuya.
References
-
Frias JP et al.,New England Journal yeMishonga, 2021.
-
Jastreboff AM et al.,New England Journal yeMishonga, 2022 (SURMOUNT-1).
-
Ludvik B et al.,Lancet, 2021.
-
Eli Lilly Clinical Data, SURPASS Miedzo 1-5.
Nguva yekutumira: Oct-04-2025